Improving glioblastoma treatment by changing the tumor environment
Reprogramming the tumormicroenvironment to improve immunotherapy of glioblastoma
This study is looking at ways to make immune treatments work better for people with glioblastoma, a tough type of brain cancer, by changing the environment around the tumor to help the immune system fight it more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11051108 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain cancer with few effective treatments. The team is investigating how to enhance the effectiveness of immune therapies by altering the tumor microenvironment, which is currently suppressing immune responses. They are exploring the role of Wnt signaling in this process and testing a combination of a Wnt signaling inhibitor and an anti-PD-1 antibody in preclinical models. The goal is to increase the presence of immune cells that can attack the tumor and reduce the cells that inhibit this response.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with newly diagnosed or recurrent glioblastoma who have limited treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates for patients.
How similar studies have performed: While immune checkpoint blockers have shown success in other cancers, their application in glioblastoma has been largely unsuccessful, making this approach novel and potentially groundbreaking.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Jain, Rakesh K. — Massachusetts General Hospital
- Study coordinator: Jain, Rakesh K.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.